Latest Research
12 Articles
FDA Approves Tumor Treating Fields For Locally Advanced Disease
Dr. Vincent Picozzi explains how the recently approved tumor treating fields device is changing the game for pancreatic cancer patients.
An Update on Drugs for KRAS Mutations
Drugs for KRAS are the focus of a number of clinical trials, and Dr. Allyson Ocean comments on the status of this research.
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
New Neoadjuvant Treatment in Trials
Dr. Brian Wolpin provides an analysis of the latest data on a new neoadjuvant treatment for tumors that can be removed.
Rewinding 2025: A Year in Pancreatic Cancer Research
We take a look back at the research developments in 2025: KRAS, earlier detection and screening, vaccines, and clinical trials.
A Pancreas-Specific Blood Test Reaches Key Validation Milestones
Dr. Bryson Katona explains the advances in the latest pancreas-specific early detection blood test, to identify cancer at stage I and II.
The Future’s So Bright
Meet this year’s group of bright young scientists, who are setting the pace for pancreatic cancer research.
Stand Up, Speak Out
Dr. Elizabeth Jaffee outlines all the ways YOU can stand up for research and speak out to make sure funding for science is not cut further.
The Latest Research from the 2025 AACR Special Conference
Highlights from the 2025 AACR Special Conference on pancreatic cancer research include updates on drugs that work on KRAS, AI and early detection, and biomarkers.
Novel Oral Drug Shows Promise
Dr. Barbara Ma provides context for the nine-month data on a clinical trial of the novel drug atebimetinib and standard chemo.
Study Finds Rare Immunotherapy Exceptional Responders
Immunotherapy is not very effective against pancreatic cancer, but Dr. Jordan Winter is taking a closer look at patients who benefitted to see what’s different about them.
PASS-01 Trial Results: Filling the Gaps in Personalized Medicine
The PASS-01 trial results provide data to help clarify how the subtypes of pancreatic cancer respond to the two main treatment protocols.